A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped IDMC recommended that enrolment be stoped, as the EFS hazard ratio and associated p-value crossed the futility boundary specified in protocol (July 2020).

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Ibrutinib
DRUG: Rituximab
DRUG: Ifosfamide
DRUG: Carboplatin
DRUG: Etoposide
DRUG: Vincristine
DRUG: Idarubicin
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]